$ZTS

A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Now

Zoetis (ZTS) and Badger Meter (BMI) have dropped 52% and 34% from their 52-week highs, respectively. Zoetis trades at 13 times FCF, while Badger Meter trades at 29 times earnings. Both companies offer dividends and are seen as undervalued by the author, who expects long-term growth.

Original reporting
Published Oct 9, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Now — source image
Decision brief

The 30-second read

$ZTSNeutralLow
01

Why it matters

No new corporate events are disclosed; the recommendation relies on valuation arguments.

02

Market read

Limited relevance; the piece may influence a niche of dividend‑seeking investors but lacks fresh material.

03

What to watch

Potential regulatory changes in animal health and water infrastructure spending could affect long‑term growth.

Relevance 4/10Novelty 2/10Timing: none

Background

The article is an opinion piece recommending two dividend stocks that have underperformed during a market rotation toward growth names.

Company-level read

Ticker impact

$ZTSNeutralMedium confidence
Context

Zoetis is highlighted as a dividend stock that has fallen 52% from its 52‑week high, with recent sales dip and modest earnings growth.

Expected impact

possible slight upward pressure as value investors target the low multiple

Evidence & confidence

The article provides a qualitative buy case without new data; any price move would be driven by valuation re‑rating rather than a concrete catalyst.

$BMINeutralMedium confidence
Context

Badger Meter is presented as a dividend stock down 34% from its 52‑week high, with recent sales slowdown and a shift toward SaaS.

Expected impact

potential modest upside as investors re‑price the lower multiple

Evidence & confidence

The piece offers a buy recommendation based on valuation, not a new event; any move would stem from perception changes.

Market effects

Highlights a broader rotation into dividend‑focused stocks amid AI hype, but no sector‑wide catalyst.

U.S. equity market sentiment may see slight tilt toward value names.

Limited; the article is U.S.‑centric and opinion‑based.

Counterpoint

The stocks may remain pressured if earnings and sales trends do not improve, making the dividend yield insufficient compensation.

Key entities

  • Zoetis

    Animal health company (ticker ZTS).

  • Badger Meter

    Smart water metering company (ticker BMI).

Related articles

$PFEHighAI 9/10

Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?

Pfizer (PFE) raised its 2026 revenue guidance by $500M, while Zoetis (ZTS) cut its outlook, expecting a 1-3% decline. Pfizer's growth is driven by drugs like Eliquis and Padcev, while Zoetis faces market share pressures. Pfizer aims for high single-digit revenue CAGR from 2028-2033, with $9.7B in expected savings. Zoetis is investing in dermatology and adjusting prices to combat competition.

$ZTSHighAI 8/10

Zoetis (ZTS) Shares Drop After Earnings Revision

Impax US Sustainable Economy Fund reported Q2 2026 performance, with shares in Zoetis (ZTS) dropping due to earnings revision. Zoetis, an animal health company, faced sales headwinds for its Librela product and delayed next-gen launches. The stock closed at $75.81 on September 4, 2026, down 50.04% year-over-year. The fund noted Zoetis' sustainability profile but sees greater upside in AI stocks.

$VIAVMed

Inspection Instruments Stocks Q2 Earnings Review: Keysight (NYSE:KEYS) Shines

Viavi Solutions (down 10.9%) had the fastest revenue growth among inspection instruments stocks, while Badger Meter (NYSE:BMI, down 9.3%) reported a 6.6% revenue decline. Itron (NASDAQ:ITRI, up 12.2%) missed revenue estimates but exceeded EBITDA and EPS guidance. Teledyne (NYSE:TDY, down 3.7%) reported a 9.8% revenue increase, beating expectations. Market risks have shifted from AI to geopolitics and back to fundamentals.

$ZTSHighAI 9/10

Zoetis (ZTS) Stock Climbed, So What Is Driving Attention Now?

Zoetis (ZTS) stock rose 3.61% in a day and 6.52% in a week after FDA authorized Simparica Trio for treating New World screwworm. Despite recent gains, shares are down 38.27% year-to-date and 48.95% in a year. The company lowered revenue and earnings guidance, with a 11% YoY decline in U.S. Companion Animal segment revenue. ValueInvestingSubstack values Zoetis at $92.92, suggesting a 16.3% undervaluation.